Shionogi Co-promotes Flu Diagnostic Kit Along With Peramivir
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Shionogi started co-promoting a flu virus diagnostic kit developed by Tokyo-based Mizuho Medy in Japan. The Quick Chaser Flu A,B can quickly detect the flu virus and will be marketed along with Shionogi's newly launched flu drug Rapiacta (peramivir) injection. The co-promotion deal will enable Shionogi to provide flu patients with a full line of services from detection to treatment. The diagnostic kit is priced at ¥11,000 for 10 uses. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.